Avacta Group plc, a life sciences company that develops targeted oncology drugs and diagnostics, has dosed the first patient in the US as part of its phase 1 multi-center trial to evaluate the safety and tolerability of AVA6000.
This is a novel, tumour-targeted form of doxorubicin and Avacta’s first therapeutic product that is based on the company’s proprietary pre|CISION™ technology, under its Investigational New Drug (IND) Application.
The dose-escalation study for locally advanced or metastatic selected solid tumors, which are known to be FAP-positive, will take place at the Memorial Sloan Kettering Cancer Center in New York. More information on the trial can be found at www.clinicaltrials.gov (NCT04969835).
Dr Alastair Smith, CEO of Avacta Group plc, noted that New York and Seattle US trial sites, along with other locations in the UK and US, would play a crucial role in both the dose escalation and dose expansion phases of the multi-center trial, which is expected to start in the second half of the year.
Dosing the first patient in the US is a significant milestone and reflects the ongoing progress in the ALS-6000-101 clinical trial and the Therapeutics Division as a whole, he added.
